Concepedia

Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma

John A. Boockvar, Apostolos John Tsiouris, Christoph P. Hofstetter, I. Kovanlikaya, Sherese Fralin, Kartik Kesavabhotla, Stephen Seedial, Susan C. Pannullo, Theodore H. Schwartz, Philip E. Stieg,

Journal of neurosurgery · 2010 · 159 citations · 32 references

DOIFull text

Open access

Abstract

The authors conclude that SIACI of mannitol followed by bevacizumab (up to 15 mg/kg) for recurrent malignant glioma is safe and well tolerated. Magnetic resonance imaging shows that SIACI treatment with bevacizumab can lead to reduction in tumor area, volume, perfusion, and T2-weighted/FLAIR signal.

References

32

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.7K citations · Full text

, , +23

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

, , +20

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Clinical Cancer Research · 2007 · 1.1K citations · Full text

Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Daniel Guillaume, Nancy D. Doolittle, Seymur Gahramanov et al. · PubMed · 2010 · 420 citations · Full text

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

Philip H. Gutin, Fábio M. Iwamoto, Kathryn Beal et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 371 citations

, , +9